Auris Medical's Keyzilen flunks second late-stage tinnitus study; shares down 30% after hours

|About: Auris Medical Holding (EARS)|By:, SA News Editor

Nano cap Auris Medical (NASDAQ:EARS) slumps 30% after hours in response to its announcement that the second Phase 3 clinical trial, TACTT3, assessing Keyzilen in patients with acute inner ear tinnitus failed to achieve the primary endpoint of a statistically valid improvement in Tinnitus Functional Score from baseline to day 84 versus placebo.

An earlier Phase 3, TACTT2, was also unsuccessful.

Previously: Auris Medical's lead product candidate flunks late-stage study; shares plummet 42% premarket (Aug. 18, 2016)

Subscribe for full text news in your inbox